Objective/background Despite the success of chimeric antigen receptor (CAR) T-cell therapy
in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment …

Background In patients with relapsed or refractory B cell acute lymphoblastic leukemia or B
cell non‐Hodgkin lymphoma (r/r B‐ALL/B‐NHL) with low CD3+ cells in the peripheral blood …

Hematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen
receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma …

Simple Summary Cellular immunotherapy has achieved great progress in the treatment of
hematological malignancies, and cell therapy may become the main force in the treatment of …

The application of chimeric antigen receptor (CAR) T cells in the management of
hematological malignancies has emerged as a noteworthy therapeutic breakthrough …

嵌合抗原受体(CAR) T 细胞在血液肿瘤治疗中的有效性得到广泛认可. CAR-T
相关不良反应有细胞因子释放综合征(cytokine release syndrome, CRS) …

Introduction CD19-directed chimeric antigen receptor T cells (CAR T) are approved for
treatment of adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL) following …

Introduction: Regulatory activities aim to facilitate the safe use of novel therapeutics such as
genetically engineered chimeric antigen receptor (CAR)-T cells. Toxicities associated with …

In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study
identified a group of patients with refractory aggressive B cell lymphoma (ABCL) with …

Los medicamentos de terapia avanzada han emergido en los últimos años como nuevas
estrategias farmacoterapéuticas. En este contexto, los servicios de farmacia hospitalaria nos …